EP Studies Should Return To Basics, FDA Says; CRT Trial Endpoints Assessed
This article was originally published in The Gray Sheet
Executive Summary
CDRH Division of Cardiovascular Devices Director Bram Zuckerman is warning manufacturers of an over-reliance on surrogate endpoints that the agency has observed in electrophysiology device trials